Economic Costs of Rotavirus Gastroenteritis and Cost-Effectiveness of Vaccination in Developing Countries

This article, published in The Journal of Infectious Diseases, evaluated the economic burden of rotavirus and the cost-effectiveness of vaccination from the health care perspective. The authors found that rotavirus vaccination would annually prevent 228,000 deaths, 13.7 million hospital visits, and 8.7 million disability-adjusted life-years, saving US$188 million in treatment costs and US$243 million in societal costs. They concluded that vaccination is a cost-effective strategy to reduce the health and economic burden of rotavirus, though it depends on vaccine price and reaching children at highest risk of mortality.

Author(s): Rheingans RD, Antil L, Dreibelbis R, Podewils LJ, Bresee JS, Parashar UD

Published: 2009

  • Visit web page (English)

    (Located at jid.oxfordjournals.org)

    Citation: Rheingans RD, Antil L, Dreibelbis R, Podewils LJ, Bresee JS, Parashar UD. Economic Costs of Rotavirus Gastroenteritis and Cost-Effectiveness of Vaccination in Developing Countries. The Journal of Infectious Diseases. 2009;200(Suppl 1):S16-S27.